Gatien Moriceau
Gatien Moriceau
Assistant Professor at UCLA
Verified email at mednet.ucla.edu
Title
Cited by
Cited by
Year
RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF (V600E)
PI Poulikakos, Y Persaud, M Janakiraman, X Kong, C Ng, G Moriceau, ...
Nature 480 (7377), 387, 2011
13832011
Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy
H Shi, W Hugo, X Kong, A Hong, RC Koya, G Moriceau, T Chodon, R Guo, ...
Cancer discovery, 2013
8352013
Melanoma whole-exome sequencing identifies V600EB-RAF amplification-mediated acquired B-RAF inhibitor resistance
H Shi, G Moriceau, X Kong, MK Lee, H Lee, RC Koya, C Ng, T Chodon, ...
Nature communications 3, 724, 2012
6742012
Non-genomic and immune evolution of melanoma acquiring MAPKi resistance
W Hugo, H Shi, L Sun, M Piva, C Song, X Kong, G Moriceau, A Hong, ...
Cell 162 (6), 1271-1285, 2015
4262015
MDM4 is a key therapeutic target in cutaneous melanoma
A Gembarska, F Luciani, C Fedele, EA Russell, M Dewaele, S Villar, ...
Nature medicine 18 (8), 1239, 2012
2922012
Tunable-combinatorial mechanisms of acquired resistance limit the efficacy of BRAF/MEK cotargeting but result in melanoma drug addiction
G Moriceau, W Hugo, A Hong, H Shi, X Kong, CY Clarissa, RC Koya, ...
Cancer cell 27 (2), 240-256, 2015
2672015
A novel AKT1 mutant amplifies an adaptive melanoma response to BRAF inhibition
H Shi, A Hong, X Kong, RC Koya, C Song, G Moriceau, W Hugo, ...
Cancer discovery, 2013
1552013
Preexisting MEK1 exon 3 mutations in V600E/KBRAF melanomas do not confer resistance to BRAF inhibitors
H Shi, G Moriceau, X Kong, RC Koya, R Nazarian, GM Pupo, ...
Cancer discovery, 2012
1002012
Zoledronic acid potentiates mTOR inhibition and abolishes the resistance of osteosarcoma cells to RAD001 (Everolimus): pivotal role of the prenylation process
G Moriceau, B Ory, L Mitrofan, C Riganti, F Blanchard, R Brion, C Charrier, ...
Cancer Research, canres. 0578.2010, 2010
952010
Recurrent tumor cell-intrinsic and-extrinsic alterations during MAPKi-induced melanoma regression and early adaptation
C Song, M Piva, L Sun, A Hong, G Moriceau, X Kong, H Zhang, S Lomeli, ...
Cancer discovery, CD-17-0401, 2017
942017
Vemurafenib resistance reprograms melanoma cells towards glutamine dependence
JE Hernandez-Davies, TQ Tran, MA Reid, KR Rosales, XH Lowman, ...
Journal of translational medicine 13 (1), 210, 2015
832015
Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy. Cancer Discov. 2014; 4: 80–93. doi: 10.1158/2159-8290
H Shi, W Hugo, X Kong, A Hong, RC Koya, G Moriceau, T Chodon, R Guo, ...
CD-13-0642.[PMC free article][Abstract][Cross Ref], 0
80
Exploiting drug addiction mechanisms to select against MAPKi-resistant melanoma
A Hong, G Moriceau, L Sun, S Lomeli, M Piva, R Damoiseaux, SL Holmen, ...
Cancer discovery, 2017
492017
Exploiting drug addiction mechanisms to select against
A Hong, G Moriceau, L Sun, S Lomeli, M Piva, R Damoiseaux, SL Holmen, ...
49*
JUN dependency in distinct early and late BRAF inhibition adaptation states of melanoma
B Titz, A Lomova, A Le, W Hugo, X Kong, J Ten Hoeve, M Friedman, H Shi, ...
Cell discovery 2, 16028, 2016
482016
Therapeutic approach of primary bone tumours by bisphosphonates
G Moriceau, B Ory, B Gobin, F Verrecchia, F Gouin, F Blanchard, F Redini, ...
Current Pharmaceutical Design 16 (27), 2981-2987, 2010
442010
Imatinib mesylate exerts anti-proliferative effects on osteosarcoma cells and inhibits the tumour growth in immunocompetent murine models
B Gobin, G Moriceau, B Ory, C Charrier, R Brion, F Blanchard, F Redini, ...
PloS one 9 (3), e90795, 2014
362014
mTOR inhibitors (rapamycin and its derivatives) and nitrogen containing bisphosphonates: bi-functional compounds for the treatment of bone tumours
B Ory, G Moriceau, F Redini, D Heymann
Current medicinal chemistry 14 (13), 1381-1387, 2007
342007
Regulation of osteoprotegerin pro-or anti-tumoral activity by bone tumor microenvironment
F Lamoureux, G Moriceau, G Picarda, J Rousseau, V Trichet, F Rédini
Biochimica et Biophysica Acta (BBA)-Reviews on Cancer 1805 (1), 17-24, 2010
322010
Farnesyl diphosphate synthase is involved in the resistance to zoledronic acid of osteosarcoma cells
B Ory, G Moriceau, V Trichet, F Blanchard, M Berreur, F Rédini, M Rogers, ...
Journal of cellular and molecular medicine 12 (3), 928-941, 2008
312008
The system can't perform the operation now. Try again later.
Articles 1–20